NCT03603132View on ClinicalTrials.gov

A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 14, 2018

Primary Completion Date

August 17, 2018

Study Completion Date

August 17, 2018

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Hetrombopag Olamine

7.5mg in each cycle

Trial Locations (1)

410013

The third xiangya hospital Hospital,of central south university, Changsha

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03603132 - A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics | Biotech Hunter | Biotech Hunter